PharmaCyte Biotech, Inc.
PMCB
$0.9411
$0.00730.78%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.64% | -51.66% | -23.96% | -40.49% | 31.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.66% | -48.62% | -21.47% | -38.86% | 29.10% |
| Operating Income | 10.66% | 48.62% | 21.47% | 38.86% | -29.10% |
| Income Before Tax | 772.47% | -391.57% | -152.68% | 835.76% | 1,166.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 772.47% | -391.57% | -152.68% | 835.76% | 1,166.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 772.47% | -391.57% | -152.68% | 835.76% | 1,166.27% |
| EBIT | 10.66% | 48.62% | 21.47% | 38.86% | -29.10% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 620.15% | 33.00% | 17.82% | 506.19% | -4,184.51% |
| Normalized Basic EPS | -138.40% | 720.00% | 15.03% | 165.48% | 5,793.18% |
| EPS Diluted | 620.15% | 33.00% | 17.82% | 506.19% | -4,184.51% |
| Normalized Diluted EPS | -138.40% | 720.00% | 15.03% | 165.48% | 5,793.18% |
| Average Basic Shares Outstanding | -17.91% | -19.14% | -12.87% | -37.58% | -53.09% |
| Average Diluted Shares Outstanding | -17.91% | -19.14% | -12.87% | -37.58% | -53.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |